Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study

Critical Care

Volumn 16, Issue 3, 2012, Pages

  Guidet, Bertrand ^a,b,c   Martinet, Olivier ^d   Boulain, Thierry ^e   Philippart, Francois ^f,g   Poussel, Jean F ^h   Maizel, Julien ⁱ   Forceville, Xavier ^j   Feissel, Marc ^k   Hasselmann, Michel ^d   Heininger, Alexandra ^l   Van Aken, Hugo ^m  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL CIVIL   (France)

^e CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^f SAINT JOSEPH HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Centre Hospitalier de Metz   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER DE MEAUX   (France)

^k Réanimation et Maladies Infectieuses   (France)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; SODIUM CHLORIDE; HES 130-0.4; HETASTARCH DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FLUID RESUSCITATION; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FLUID THERAPY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; FLUID THERAPY; HEMODYNAMICS; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 84861334037     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/11358     Document Type: Article

References (31)

1. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010, 36:222-231. 10.1007/s00134-009-1738-3, 2826633, 20069275.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, . Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169, Early Goal-Directed Therapy Collaborative Group.
3. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, , et al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437, International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases.
4. Schortgen F, Girou E, Deye N, Brochard L, . CRYCO Study Group The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008, 34:2157-2168. 10.1007/s00134-008-1225-2, 18685828, CRYCO Study Group.
5. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001, 357:911-916. 10.1016/S0140-6736(00)04211-2, 11289347.
6. Brunkhorst F, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, . German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958, German Competence Network Sepsis (SepNet).
7. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005, 44:681-699. 10.2165/00003088-200544070-00002, 15966753.
8. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products - different effects. Anesthesiology 2009, 111:187-202. 10.1097/ALN.0b013e3181a7ec82, 19512862.
9. Crystalloid vs. Hydroxyethyl Starch Trial (CHEST) Management Committee The Crystalloid vs. Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med 2011, 37:816-823. Crystalloid vs. Hydroxyethyl Starch Trial (CHEST) Management Committee.
10. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212. 10.1186/cc2872, 522841, 15312219.
11. Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008, 23:1569-1574. 10.1093/ndt/gfn009, 18281319.
12. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238. 10.1016/S0140-6736(05)74811-X, 15811456.
13. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmayer A, Boldt J. Effect of a new hydroxyetyl starch (HES) specification [6% HES (130/0.4)] on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999, 17:119-125.
14. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidne-transplant recipients. Lancet 1996, 348:1620-1622. 10.1016/S0140-6736(96)07588-5, 8961992.
15. Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 2008, 100:504-548. 10.1093/bja/aen001, 18256055.
16. Hokema F, Ziganshyna S, Bartels M, Pietsch UC, Busch T, Jonas S, Kaisers U. Is perioperative low molecular weight hydroxyethyl starch infusion a risk factor for delayed graft function in renal transplant recipients?. Nephrol Dial Transplant 2011, 26:3373-3378. 10.1093/ndt/gfr017, 21427075.
17. Muller L, Jaber S, Molinari N, Favier L, Larché J, Motte G, Lazarovici S, Jacques L, Alonso S, Leone M, Constantin JM, Allaouchiche B, Suehs C, Lefrant JY, . the AzuRéa Group Fluid management and risk factors for renal dysfunction in patients with severs sepsis and/or septic shock. Crit Care 2012, 16:R34. 10.1186/cc11213, 22377234, the AzuRéa Group.
18. Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, Xue P, Lu HM, Ke NW, Zhang ZD, Li QS. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. Pancreas 2011, 40:1220-1225. 10.1097/MPA.0b013e3182217f17, 21775917.
19. Boussekey N, Darmon R, Langlois J, Alfandari S, Devos P, Meybeck A, Chiche A, Georges H, Leroy O. Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care 2010, 14:R40. 10.1186/cc8920, 2887149, 20298543.
20. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 130/0.4 (Voluven®) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: A prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 2008, 25:986-994. 10.1017/S026502150800447X, 18492315.
21. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003, 96:1453-1459.
22. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, Rodrigus I, Daper A, Trenchant A. Hydroxyethyl starch 130/0.4 vs. modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005, 101:629-634. 10.1213/01.ANE.0000175216.53374.27, 16115963.
23. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: The FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 2011, 107:693-702. 10.1093/bja/aer229, 21857015.
24. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment. Anesth Analg 2002, 95:544-551.
25. Ellger B, Freyhoff J, Van Aken H, Booke M, Marcus MAE. High-dose volume replacement using HES 130/0.4 during major surgery: Impact on coagulation and incidence of postoperative itching. Ned Tijdschr Anesth 2006, 19:63-68.
26. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008, 107:382-390. 10.1213/ane.0b013e31817e6eac, 18633012.
27. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003, 4:331-338. 10.2165/00126839-200304060-00001, 14584961.
28. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997, 136:553-559. 10.1111/j.1365-2133.1997.tb02140.x, 9155957.
29. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest 2002, 121:2000-2008. 10.1378/chest.121.6.2000, 12065368.
30. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R, . SAFE Study Investigators Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011, 37:86-96. SAFE Study Investigators.
31. Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, Pettilä V, , et al. Scandinavian Critical Care Trials Group Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S-Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011, 12:24. 10.1186/1745-6215-12-24, 3040153, 21269526, Scandinavian Critical Care Trials Group.